TSC-101
Cell therapy
Evidence outlook · program status
On hold (2026-09-02), as a strategic decision by the sponsor
TScan prioritised its preclinical solid-tumor programme and paused further enrolment in the Phase 3 ALLOHA-2 study of TSC-101. The trials below are the program's evidence history; no evidence signal is assigned while development is paused.
Company guidance: topline data expected mid-2028 (NCT07702578; TScan Therapeutics, Inc., 12 Aug 2026). “First patient dosed in Phase 3 ALLOHA-2 study; topline readout expected mid-2028” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ALLOHA-2 NCT07702578 · AML Registry: NCT07702578 | 3 | Relapse-free survival (RFS) (3 years) 2029-06 | In progress: results expected 1 Jun 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Hematologic Malignancies: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| TSC-101: this drug | Phase 3 | Cell therapy | HA-2 (minor histocompatibility antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| TSC-100 | Phase 1 | Cell therapy | HA-1 minor histocompatibility antigen (HLA-A*02:01) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Development is on hold since 2026-09-02 (source ↗). ClinicalTrials.gov still lists the estimated primary-completion dates below; they may not read out as listed.
2029 (1)
June 2029 (1)
Company guidance: topline data expected mid-2028 (TScan Therapeutics, Inc., 12 Aug 2026). “First patient dosed in Phase 3 ALLOHA-2 study; topline readout expected mid-2028” Source ↗